Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G:超过5%持股股东披露文件-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q:2024财年三季报
Larimar Therapeutics | 8-K:Larimar Therapeutics公布2024年第三季度运营和财务业绩
Larimar Therapeutics | 10-Q:2024财年二季报
Larimar Therapeutics | 8-K:Larimar Therapeutics公布2024年第二季度运营和财务业绩
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 4:持股变动声明-董事 Flynn James E
Larimar Therapeutics | 4:持股变动声明-董事 Hamilton Thomas Edward
Larimar Therapeutics | 4:持股变动声明-董事 Truitt Joseph
Larimar Therapeutics | 4:持股变动声明-董事 SHERMAN JEFFREY W
Larimar Therapeutics | 4:持股变动声明-董事 LEFF JONATHAN S
Larimar Therapeutics | 4:持股变动声明-董事 THOMAS FRANK E
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | EFFECT:其他
Larimar Therapeutics | CORRESP:信函
暂无数据
暂无数据